JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical…
This Private Placement Investment Comes in Addition to a $5 Million Investment from Core 4 Capital Corp Which Closed in April…
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company,…
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm…
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…
SaaS Healthcare Leader Joins MEDITECH Alliance to Optimize Patient Intake and Payment ProcessesBOWIE, Md., June 28, 2024 (GLOBE NEWSWIRE) --…
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s…